• Aucun résultat trouvé

p16INK4A inactivation mechanisms in non-small-cell lung cancer patients occupationally exposed to asbestos.

N/A
N/A
Protected

Academic year: 2021

Partager "p16INK4A inactivation mechanisms in non-small-cell lung cancer patients occupationally exposed to asbestos."

Copied!
3
0
0

Texte intégral

(1)

HAL Id: inserm-00388198

https://www.hal.inserm.fr/inserm-00388198

Submitted on 28 May 2009

HAL is a multi-disciplinary open access

archive for the deposit and dissemination of sci-entific research documents, whether they are pub-lished or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

p16INK4A inactivation mechanisms in non-small-cell

lung cancer patients occupationally exposed to asbestos.

Pascal Andujar, Jinhui Wang, Alexis Descatha, Françoise Galateau-Sallé, Issam Abd-Alsamad, Marie-Annick Billon-Galland, Hélène Blons, Bénédicte

Clin, Claire Danel, Bruno Housset, et al.

To cite this version:

Pascal Andujar, Jinhui Wang, Alexis Descatha, Françoise Galateau-Sallé, Issam Abd-Alsamad, et al.. p16INK4A inactivation mechanisms in non-small-cell lung cancer patients occupationally exposed to asbestos.. Lung Cancer, Elsevier, 2010, 67 (1), pp.23-30. �10.1016/j.lungcan.2009.03.018�. �inserm-00388198�

(2)

LEGEND TO FIGURES

Figure 1. Immunodetection of p16

INK4A

by immunohistochemistry in NSCLC

patients

A: Positive control of p16INK4A

B: Positive immunostaining of p16INK4A in a lung adenocarcinoma case (× 200)

C: Lack of p16INK4A expression in a lung adenocarcinoma case (× 200)

Figure 2. Representative patterns of aberrant methylation promoter of

P16/CDKN2A

gene in NSCLC patients.

Primer sets used for amplification are designated as unmethylated (UM) or methylated (M). Twenty µl of PCR product were run on 2.5% agarose gel stained with ethidium bromide, and visualized under UV illumination. T: tumor tissue; N: normal lung tissue; M: DNA 50 bp ladder; NM: negative control with methylated

sequence specific primer; NUM negative control with unmethylated sequence specific

primer.

Figure 3. FISH hybridization

. Dual-color FISH with PONC0921 probe.

(P16/CDKN2A specific DNA probe is direct-labeled with rhodamine and the

chromosome 9 classical satellite probe is direct-labeled with fluorescein).

A

: Normal lung tissue used as positive control showed two red signals and two green signals.

B

: NSCLC case showing two green signals and one red signal indicating a loss of heterozygosity of P16/CDKN2A gene.

(3)

Références

Documents relatifs

In conclusion, ceritinib (750 mg·day −1 ) demonstrated similar efficacy for crizotinib-pretreated patients with ALK + NSCLC in the TAU program as is seen in clinical trials and with

[25] reported the good prognostic value of ERCC1 high-intensity (above median value) tumour immunostaining, and the predictive value for lower overall survival of high expression

KEYNOTE-042 phase 3 clinical trial enrolled patients with PD-L1 expression ≥1% advanced NSCLC to compare pembrolizumab vs platinum-based chemotherapy in first-line

Le but de cette étude était d’évaluer l’effet d’une intervention infirmière basée sur la théorie de l’auto-régulation : l’intervention sur le focus

Cells in the CD8-GZMH cluster show limited robustness in clustering and share numerous clonal TCRs with all other CD8 + T cell clusters, indicating that early-memory like

The combination of (R)- crizotinib, CDDP and PD-1 blockade achieved a 100% cure rate (15 out of 15 mice) in yet another orthotopic NSCLC model, namely Lewis lung carcinoma-1

RECIST progression at first evaluation and ≥ two-fold increase in TGR between the REF and the EXP periods Death within three months of nivolumab initiation TGK ratio